@conference{1adbc4028c58447cb735acaf073b1e0a,
title = "Tabelecleucel in combination with pembrolizumab (Pembro) in platinum-pretreated, recurrent/metastatic Epstein-Barr virus (EBV)-positive nasopharyngeal carcinoma (EBV+NPC).",
author = "Siu, \{Lillian L.\} and Joshua Bauml and Douglas Adkins and Colevas, \{A. Dimitrios\} and Perez, \{Cesar Augusto\} and Choe, \{Jennifer Hsing\} and Yang Zhang and Wen Shi and Navarro, \{Willis H.\} and Missak Haigentz and Guilherme Rabinowits and Pfister, \{David G.\}",
note = "TPS6092 Background: Approximately 25\% of patients (pts) with NPC develop RM disease, which has a poor prognosis (median overall survival [mOS]: 12-16 mo), despite standard treatments with radiation and/or chemotherapy. NPC is an EBV-associated cancer in which programmed cell death ligand 1 (PD-L1) expression is upregulated upon EBV activation.; Journal of Clinical Oncology ; Conference date: 01-01-2020",
year = "2019",
month = may,
day = "26",
doi = "10.1200/JCO.2019.37.15\_SUPPL.TPS6092",
language = "American English",
}